Your browser is no longer supported. Please, upgrade your browser.
Titan Pharmaceuticals, Inc.
Index- P/E6.64 EPS (ttm)0.26 Insider Own6.97% Shs Outstand9.86M Perf Week6.17%
Market Cap16.24M Forward P/E- EPS next Y-1.19 Insider Trans0.00% Shs Float9.18M Perf Month-14.43%
Income-3.80M PEG- EPS next Q-0.35 Inst Own19.70% Short Float2.62% Perf Quarter-25.22%
Sales3.50M P/S4.64 EPS this Y79.90% Inst Trans- Short Ratio1.95 Perf Half Y-26.81%
Book/sh0.89 P/B1.93 EPS next Y11.20% ROA- Target Price- Perf Year-59.77%
Cash/sh1.03 P/C1.67 EPS next 5Y- ROE- 52W Range1.57 - 8.85 Perf YTD-47.72%
Dividend- P/FCF- EPS past 5Y54.60% ROI-181.30% 52W High-80.56% Beta0.81
Dividend %- Quick Ratio4.20 Sales past 5Y23.70% Gross Margin87.40% 52W Low9.55% ATR0.10
Employees12 Current Ratio4.20 Sales Q/Q-69.20% Oper. Margin- RSI (14)38.89 Volatility9.58% 5.66%
OptionableYes Debt/Eq0.00 EPS Q/Q88.40% Profit Margin- Rel Volume0.58 Prev Close1.78
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume123.28K Price1.72
Recom2.00 SMA20-5.97% SMA50-14.78% SMA200-34.10% Volume71,090 Change-3.37%
Jun-26-19Initiated Maxim Group Buy $4
Nov-10-17Downgrade ROTH Capital Buy → Neutral
Oct-12-21 08:00AM  
Aug-20-21 02:52PM  
Aug-04-21 09:34AM  
Jun-23-21 08:00AM  
Mar-31-21 04:30PM  
Feb-01-21 07:30AM  
Jan-15-21 09:15AM  
Dec-16-20 08:00AM  
Dec-01-20 04:56AM  
Nov-30-20 12:50PM  
Nov-16-20 08:45AM  
Nov-02-20 08:00AM  
Oct-30-20 08:14AM  
Oct-28-20 03:00PM  
Oct-26-20 06:30AM  
Oct-15-20 08:00AM  
Sep-24-20 09:00AM  
Sep-18-20 04:45PM  
Sep-16-20 01:05PM  
Sep-15-20 08:30AM  
Sep-14-20 08:30AM  
Aug-26-20 05:45AM  
Aug-14-20 08:45AM  
Aug-10-20 04:30PM  
Jul-08-20 08:00AM  
Jun-24-20 08:00AM  
Jun-16-20 08:00AM  
Jun-01-20 05:20AM  
May-15-20 08:45AM  
May-11-20 04:03PM  
Apr-09-20 06:15AM  
Apr-02-20 09:47PM  
Mar-31-20 12:43PM  
Mar-30-20 04:03PM  
Mar-26-20 08:00AM  
Mar-05-20 09:00AM  
Feb-18-20 08:55AM  
Jan-13-20 08:00AM  
Jan-07-20 09:15AM  
Dec-30-19 08:00AM  
Dec-17-19 10:30AM  
Dec-04-19 01:22PM  
Dec-03-19 09:00AM  
Nov-25-19 05:15AM  
Nov-14-19 04:03PM  
Nov-07-19 04:30PM  
Oct-22-19 08:00AM  
Oct-18-19 10:23AM  
Oct-16-19 09:20AM  
Oct-01-19 08:00AM  
Sep-18-19 08:00AM  
Aug-30-19 08:01PM  
Aug-23-19 11:30AM  
Aug-17-19 09:59AM  
Aug-16-19 07:33AM  
Aug-14-19 04:03PM  
Aug-09-19 05:00PM  
Aug-07-19 09:15AM  
Jul-09-19 09:00AM  
Jul-03-19 10:54AM  
Jun-26-19 09:10AM  
Jun-04-19 07:00AM  
May-29-19 02:15PM  
May-23-19 08:10AM  
May-15-19 04:08PM  
May-13-19 07:00AM  
May-08-19 08:00PM  
May-06-19 03:12PM  
Apr-29-19 07:00AM  
Apr-12-19 05:00PM  
Apr-11-19 09:45AM  
Apr-02-19 01:06AM  
Apr-01-19 05:07PM  
Mar-28-19 07:00AM  
Mar-26-19 07:00AM  
Feb-25-19 02:20PM  
Feb-08-19 09:30AM  
Feb-01-19 02:31PM  
Jan-31-19 06:36PM  
Jan-24-19 07:00AM  
Dec-21-18 12:54PM  
Dec-10-18 10:35AM  
Nov-21-18 07:25AM  
Nov-20-18 11:15AM  
Nov-14-18 04:38PM  
Nov-08-18 07:00AM  
Nov-07-18 09:30AM  
Nov-05-18 08:55AM  
Nov-02-18 10:30AM  
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.